Wells Fargo & Company Has Lowered Expectations for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT) had its price objective decreased by investment analysts at Wells Fargo & Company from $1.75 to $1.50 in a report issued on Thursday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target indicates a potential downside of 15.49% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the stock. Cantor Fitzgerald reiterated a “neutral” rating on shares of Health Catalyst in a research report on Monday, May 11th. Weiss Ratings raised Health Catalyst from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. Canaccord Genuity Group boosted their target price on Health Catalyst from $2.00 to $3.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Citigroup dropped their target price on Health Catalyst from $2.50 to $2.00 and set a “neutral” rating for the company in a report on Tuesday. Finally, Stephens lowered their price objective on Health Catalyst from $2.00 to $1.75 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Health Catalyst presently has an average rating of “Hold” and a consensus target price of $2.93.

Health Catalyst Stock Performance

NASDAQ HCAT opened at $1.77 on Thursday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 1.69 and a current ratio of 1.69. The company has a fifty day moving average of $2.01 and a 200-day moving average of $1.69. Health Catalyst has a 52-week low of $0.96 and a 52-week high of $3.80. The company has a market capitalization of $133.59 million, a P/E ratio of -0.49 and a beta of 1.55.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. Health Catalyst had a negative return on equity of 1.57% and a negative net margin of 90.61%.The company had revenue of $70.49 million for the quarter, compared to analysts’ expectations of $69.09 million. As a group, equities research analysts predict that Health Catalyst will post -0.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in HCAT. nVerses Capital LLC bought a new stake in shares of Health Catalyst during the fourth quarter valued at approximately $25,000. Cresset Asset Management LLC bought a new stake in shares of Health Catalyst during the 2nd quarter valued at $39,000. Deutsche Bank AG purchased a new stake in shares of Health Catalyst in the 2nd quarter worth about $43,000. Focus Partners Wealth bought a new position in shares of Health Catalyst in the 1st quarter worth about $46,000. Finally, BNP Paribas Financial Markets lifted its position in Health Catalyst by 71.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 16,355 shares of the company’s stock valued at $47,000 after acquiring an additional 6,832 shares during the period. Institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.